Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Arbutus Biopharma Corp - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ABUS
Nasdaq
8731
https://www.arbutusbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Arbutus Biopharma Corp
Arbutus Announces Resignation of Board Member
- Jan 27th, 2023 12:30 pm
Vericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains?
- Jan 12th, 2023 3:24 am
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
- Jan 5th, 2023 12:30 pm
Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection
- Dec 13th, 2022 12:30 pm
Companies Like Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Invest In Growth
- Dec 8th, 2022 11:34 am
Arbutus Biopharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
- Nov 11th, 2022 10:20 am
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
- Nov 9th, 2022 1:45 pm
Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update
- Nov 9th, 2022 12:30 pm
Arbutus to Present at Jefferies London Healthcare Conference
- Nov 8th, 2022 12:30 pm
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®
- Nov 1st, 2022 8:01 pm
Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022
- Oct 31st, 2022 8:02 pm
Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update
- Oct 26th, 2022 11:30 am
Investors in Arbutus Biopharma (NASDAQ:ABUS) have made a strong return of 105% over the past three years
- Oct 9th, 2022 2:05 pm
Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End
- Sep 30th, 2022 1:00 pm
Arbutus to Present at Chardan’s 6th Annual Genetic Medicines Conference
- Sep 22nd, 2022 11:30 am
Arbutus to Participate in September Investor Conferences
- Sep 6th, 2022 11:30 am
Arbutus Biopharma Corporation's (NASDAQ:ABUS) top owners are individual investors with 43% stake, while30% is held by institutions
- Sep 6th, 2022 10:54 am
Arbutus Biopharma Announces Issuance of a New Key U.S. Patent Related to AB-729
- Aug 30th, 2022 11:30 am
Analysts Just Shipped A Dazzling Upgrade To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Estimates
- Aug 10th, 2022 10:26 am
Arbutus Biopharma (ABUS) Q2 2022 Earnings Call Transcript
- Aug 4th, 2022 11:30 pm
Scroll